What is it about?
Nutraceuticals — compounds from food sold to support health — are widely used, but most of the laboratory evidence behind them comes from immortalised cell lines or animal models that behave very differently from the human intestine. We grew miniature versions of the human colon, called organoids, from small biopsies of normal tissue taken during routine endoscopy. Each set was kept in two different states: one in which the tissue is actively growing, and one in which it has matured into the specialised cells that line the gut. We then exposed them to a controlled dose of oxidative stress, treated them with a nutraceutical, and measured what happened in three ways at once — the physical mass, density and size of each individual organoid, and the activity of its genes. The organoids responded to stress and to treatment differently depending on which state they were in, and the nutraceutical reduced the stress-related changes in gene activity. This is a pilot study on tissue from three donors.
Featured Image
Why is it important?
Claims about nutraceuticals are rarely backed by evidence from real human tissue. Our platform offers a way to test them on it, and to see both whether a compound works and how the tissue changes physically while it does. Two features make it unusual. First, it measures each organoid individually rather than averaging across a well, so small effects are not lost. Second, it compares growing and mature intestinal tissue side by side — a distinction that turns out to matter, since the two states did not respond in the same way. A compound that looks effective in one may do little in the other. The approach is not limited to nutraceuticals. The same setup can be used for drugs, food ingredients, or any question about how the human gut is damaged and how it recovers — and it arrives as regulators on both sides of the Atlantic are actively encouraging human-based models as alternatives to animal testing.
Perspectives
What I value most here is the discipline of the measurement. It would have been easier to report a single viability number and call it a result. Instead the team insisted on weighing organoids one by one and pairing that with transcriptional data, which is what turned a screening assay into something you can actually reason from. I also want to be clear about scale: three donors is a proof of principle, not a population study. The next step is more donors and a wider set of compounds. But the platform works, it runs on tissue that would otherwise be discarded, and the credit for building it belongs to Angelita Costantino and the colleagues who spent the hours at the bench.
Massimo Gulisano
Universita degli Studi di Catania
Read the Original
This page is a summary of: An integrated patient-derived colon organoids platform as a functional model for nutraceutical and stress response, iScience, June 2026, Elsevier,
DOI: 10.1016/j.isci.2026.116304.
You can read the full text:
Contributors
The following have contributed to this page
